Home

Garrett Winslow

CIK 1803773 · General Counsel · last filed 2026-07-07

Garrett Winslow is a General Counsel who has filed 14 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for DMRA, was dated Jul 7, 2026. Across all open-market trades the lifetime net is −$2.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $71.2K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$71.2K

Companies

3

Total Filings

14

Lifetime Open-Market Net

-$2.6K

Filer Profile

Reported Address
C/O DAMORA THERAPEUTICS, INC.
221 CRESCENT STREET, STE 23, BLDG 105
WALTHAM, MA 02453
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DMRA General Counsel 2,534 $28.10 $71.2K -$7.3K 2 2026-07-07
Damora Therapeutics, Inc. (GLTO) Delisted General Counsel 2,109 $28.69 $60.5K $5.6K 10 2026-01-06
F-star Therapeutics, Inc. (SBPH) Delisted General Counsel and Secretary 18,750 — — -$833 2 2020-11-23

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-07 DMRA Mixed +435 -$7.3K EDGAR
2026-03-25 DMRA Grant (A) — $0 EDGAR
2026-01-06 Damora Therapeutics, Inc. (GLTO) Delisted Mixed +425 -$5.5K EDGAR
2025-07-08 Damora Therapeutics, Inc. (GLTO) Delisted Mixed +420 -$881 EDGAR
2025-01-07 Damora Therapeutics, Inc. (GLTO) Delisted Mixed +849 -$2.6K EDGAR
2024-10-11 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2024-01-05 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2023-01-05 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2022-01-06 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2021-12-06 Damora Therapeutics, Inc. (GLTO) Delisted Buy (P) +2,000 $5.0K EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.